- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,525
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Hypertension
- Interventions
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Esophageal Diseases
- Interventions
- CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus, CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy
- Combination Product
- Lead sponsor
- Harvard Apparatus Regenerative Technology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota
- Conditions
- Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
- Interventions
- ALXN2030, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 16 more
- Conditions
- Alcohol Abuse
- Interventions
- PNF + SAF
- Behavioral
- Lead sponsor
- RAND
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Adhansia XR, Concerta
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
- Conditions
- Alcohol Abuse
- Interventions
- Bupropion, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 21 Years to 44 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Anklebot, Lokomat
- Device
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Infection, Post-operative Care
- Interventions
- Novel Microbicidal Liquid Polymer
- Device
- Lead sponsor
- Prevent-Plus LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Palmitil, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
- Conditions
- Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma
- Interventions
- Zotiraciclib (TG02), Temozolomide (TMZ)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atherosclerosis, Acute Coronary Syndrome (ACS)
- Interventions
- Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
- Interventions
- Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy
- Drug · Procedure
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Multiple Myeloma
- Interventions
- daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more
- Conditions
- Chronic Nonmalignant Pain
- Interventions
- Buprenorphine transdermal patch
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more
- Conditions
- Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
- Interventions
- ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2035
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pancreas Cancer, Oligometastatic
- Interventions
- Consolidative Radiation
- Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Camden, New Jersey • Voorhees Township, New Jersey • Dallas, Texas + 1 more
- Conditions
- Hyperoxaluria, Primary
- Interventions
- Oxabact OC5 - Oxalobacter formigenes Strain HC-1
- Biological
- Lead sponsor
- OxThera
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pain, Neoplasm, Cancer
- Interventions
- Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase
- Drug
- Lead sponsor
- Grünenthal GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 7
- States / cities
- St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more
- Conditions
- Obesity, Smoking Cessation, Bariatric Surgery Patients
- Interventions
- Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Thyroid Eye Disease
- Interventions
- Observational cohort study, Batoclimab
- Other · Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Glendora, California • Aurora, Colorado • Livonia, Michigan + 6 more
- Conditions
- Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
- Interventions
- lerodalcibep
- Drug
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Evanston, Illinois • Cincinnati, Ohio
- Conditions
- Postoperative Pain, Abdominoplasty Surgery, Multimodal Analgesia
- Interventions
- MMA regimen, ZYNRELEF kit components for administration, HTX-011, Bupivacaine Hydrochloride
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • San Antonio, Texas
- Conditions
- Macular Degeneration
- Interventions
- 0.5 mg ranibizumab
- Drug
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more